Loading...
Market
Story
Merck's Phase 3 Trial of Subcutaneous Pembrolizumab (Keytruda) Meets Primary Endpoints
Nov 19, 2024, 11:48 AM
Merck has announced that its Phase 3 trial of an under-the-skin version of Keytruda, also known as Pembrolizumab, combined with Berahyaluronidase Alfa, has met its primary endpoints. This development is part of Merck's strategy to extend the sales of Keytruda, a leading cancer immunotherapy drug. The successful study results underscore Merck's commitment to advancing oncology research and improving treatment options for patients.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Ease of Administration • 25%
Cost Effectiveness • 25%
Patient Preference • 25%
Clinical Effectiveness • 25%
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other Regions • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Merck • 25%
Roche • 25%
Another Pharmaceutical Company • 25%
No clear dominator • 25%